Professor Ira Shoulson will join Prana Biotechnology's Board of Directors as a non-Executive Director.

MELBOURNE, March 31, 2014: Prana Biotechnology (ASX:PBT/NASDAQ:PRAN) has today released the top line results of the 12-month Phase II Imaging trial in Alzheimer’s Disease (“IMAGINE” Trial), based on draft results. Prana’s PBT2 did not meet its primary endpoint of a statistically significant reduction in the levels of beta-amyloid plaques in the brains of prodromal/mild Alzheimer’s disease patients, as measured using PiB-PET Standardized Uptake Value Ratio (SUVR). Whilst there was a reduction in the overall levels of the PiB PET signal in patients treated with PBT2, the results were confounded by an atypical reduction of levels of the PiB PET signal in the placebo group as well.

MARCH 2014: Accumulation and toxicity of Alzheimer’s-related beta-amyloid independently confirmed to be dependent on copper and arrested with Prana’s proof-of-concept MPAC.

MARCH 2014: Prana Biotechnology (ASX: PBT / NASDAQ:PRAN) is presenting at the 34th Annual Cowen Healthcare Conference being held in Boston USA, 3-5 March 2014.

MELBOURNE, March 31, 2013: Access to the IMAGINE Phase 2 clinical trial investor conference call hosted on Monday 31st March Australian EDT is available via Open Briefing.

FEBRUARY 2014: MELBOURNE, Australia and NEW YORK, USA: US-based equity research analyst George B. Zavoico, Managing Director of H.C. Wainwright & Co, has published a report on Prana Biotechnology's (ASX:PBT / NASDAQ:PRAN) Phase 2 trial of PBT2 in patients with Huntington's disease, Reach2HD.

FEBRUARY 2014: MELBOURNE, Australia and NEW YORK, USA: Prana Biotechnology (ASX:PBT / NASDAQ:PRAN) has prepared a presentation for investors regarding the results of its Phase 2 clinical trial of PBT2 in patients with Huntington's disease.

FEBRUARY 2014: MELBOURNE, Australia and NEW YORK, USA: Prana Biotechnology (ASX:PBT / NASDAQ:PRAN) has today announced the results of its Reach2HD Phase 2 clinical trial investigating PBT2 as a treatment for Huntington disease.

FEBRUARY 2014: Prana Biotechnology will hold an investor conference call and webcast for professional investors on Wednesday 19th February at 9.30am Australian Eastern Daylight Savings Time (Tuesday 18th February US EST 5.30pm; US PST 2.30pm) to discuss the results of its Reach2HD Phase 2 clinical trial investigating PBT2 as a treatment for Huntington disease.

JANUARY 2014: Prana Biotechnology (ASX:PBT/ NASDAQ:PRAN), a leading innovative drug developer targeting disease modification in neurodegenerative disease, is commencing a non-deal investor roadshow in the United States with Credit Suisse.